布拉迪基宁2型受体过度表达对小鼠心血管功能的影响
Sara Metry1, Tatsiana Suvorava2, Jens W Fischer2
1Institute of Pharmacology, University Hospital, Heinrich Heine University, Düsseldorf, Germany; Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Biochemical pharmacology
|July 18, 2025
概括
在小鼠中,内皮勃拉迪基宁2型受体 (B2) 的过度表达导致轻度低血压和胸. 心血管和心脏功能基本上没有受到影响,这表明布拉迪基宁的改变可能不会破坏正常功能.
科学领域:
- 心血管生理学心血管生理学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 布拉迪基宁是一种调节血管功能的,但其对心血管的影响尚未完全理解.
- 内皮布拉迪基宁2型受体 (B2) 在布拉迪基宁信号传递中起着关键作用.
- 了解B2受体功能对于心血管健康至关重要.
研究的目的:
- 研究内皮特异性B2受体过度表达对心血管和心脏的影响.
- 确定增强的布拉迪基宁信号对血管反应的影响.
- 为了评估转基因小鼠的血压,心率和心脏功能变化.
主要方法:
- 使用了具有内皮特异性B2受体过度表达 (B2tg) 和子期对照 (B2n) 的基因工程小鼠.
- 在大动脉环上进行了ex vivo血管功能研究.
- 在体内评估内皮功能使用流介导扩张.
- 通过胸前心脏回声学评估心脏功能.
- 施用布拉迪基宁,烯酸,氧化捐赠者和特定的对抗剂.
主要成果:
- 布拉迪基宁在B2tg小鼠中诱导了血管松,对氧化合成酶 (NOS) 抑制敏感,与B2n小鼠的收缩不同.
- 在体内内皮质功能和心脏功能参数因B2过度表达而没有显著改变.
- B2tg小鼠表现出缩血压降低和心肌梗塞,被B2抗剂icatibant消除.
- B2tg小鼠的低血压独立于循环氧化酶和NOS途径.
结论:
- 内皮特异性B2过度表达会导致健康小鼠轻度低血压和心肌梗塞.
- 这些发现表明,内源勃拉迪基宁信号的中度变化可能不会严重损害心血管功能.
- 需要进一步的临床研究来评估心血管疾病中持续布拉迪基宁调节的长期安全性.
相关概念视频
01:17Antihypertensive Drugs: Action of β1 Blockers
613
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
613
01:29Heart Failure II: Pathophysiology
45
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45
01:26Adrenergic Receptors: β Subtype
2.2K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
928
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
928
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
891
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
891